Terns Pharma Stock Surges 81.6% After ASH Selection of Allosteric CML Therapy

Introduction

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is a clinical-stage biopharmaceutical company headquartered in Foster City, California. Since its founding in 2017, the firm has focused on developing small-molecule therapies with validated mechanisms of action, targeting unmet medical needs in oncology and metabolic diseases. As of November 3, 2025, Terns’s share price closed at $15.00, reflecting an 81.60% increase on a trading volume of 9,950,257 shares.

Corporate Structure and Experience

Terns Pharmaceuticals employs between 51 and 200 professionals across research, development, and corporate functions. The company is led by CEO Amy Burroughs and CMO Emil Kuriakose, MD. As a publicly traded company, Terns is subject to U.S. Securities and Exchange Commission reporting requirements and corporate governance standards.

Biopharmaceuticals by little plant

Recent Developments and News

On November 3, 2025, Terns announced that an abstract detailing clinical data for its allosteric BCR-ABL tyrosine kinase inhibitor, TERN-701, in patients with relapsed or refractory chronic myeloid leukemia (CML) was selected for oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting. TERN-701 has received Orphan Drug Designation from the U.S. Food and Drug Administration and is licensed to Hansoh for development and commercialization in mainland China, Taiwan, Hong Kong, and Macau.

Pipeline updates include Phase 2a data from the DUET study of TERN-501, a thyroid hormone receptor-beta agonist for nonalcoholic steatohepatitis (NASH), and ongoing preclinical candidate nomination for a small-molecule GIP receptor antagonist designed for obesity treatment. Preclinical data suggest that combinations of TERN-501 with semaglutide may enhance weight and fat-mass reduction compared to semaglutide alone.

On LinkedIn, Terns reported a team celebration, an announcement regarding a corporate-paralegal position, and executive discussions on advances in CML treatment. In October and early November 2025, CMO Emil Kuriakose participated in an interview with Drug Discovery News, while CEO Amy Burroughs appeared on pharmaphorum’s podcast to discuss allosteric therapies for CML. The company is also set to present two posters at the 27th Annual ESH-iCMLf John Goldman Conference in Portugal.

Financial and Strategic Analysis

The 81.60% increase in share price to $15.00 on November 3, 2025, is attributable to investor response regarding the ASH oral presentation selection and reflects the stock's sensitivity to clinical milestones. The trading volume of nearly 10 million shares indicates improved liquidity compared with prior sessions. Terns’s focus on validated targets, such as the ABL myristoyl pocket for CML, and ongoing development of combination therapies in obesity may position the company favorably in terms of regulatory incentives and partnership opportunities, as evidenced by the Hansoh licensing agreement.

Market Position and Industry Context

In the CML treatment landscape, Terns competes with approved first- and second-generation tyrosine kinase inhibitors and emerging allosteric inhibitors. The company’s allosteric approach aims to address limitations commonly associated with active-site inhibitors. In the metabolic disease sector, TERN-501 and planned GIPR antagonist programs enter a competitive market for GLP-1 receptor agonists and combination therapies targeting obesity and NASH. Terns’s expertise in small-molecule development may offer advantages in oral dosing, manufacturing scalability, and potential fixed-dose combinations.

tl;dr

On November 3, 2025, Terns Pharmaceuticals experienced an 81.60% increase in its stock price to $15.00 on nearly 10 million shares traded following the selection of an ASH abstract for TERN-701 in relapsed/refractory CML for oral presentation. The company holds Orphan Drug Designation for TERN-701 and has licensed Greater China rights to Hansoh. Key upcoming events include presentations at the ESH-iCMLf John Goldman Conference in Portugal and further data release from the DUET study for TERN-501 and a preclinical GIPR antagonist program.